These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 1372777)

  • 1. [New conservative therapeutic approaches in benign prostatic hyperplasia].
    Schulze H; Berges R; Paschold K; Senge T
    Urologe A; 1992 Jan; 31(1):8-13. PubMed ID: 1372777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Pharmacological treatment of benign prostatic hyperplasia].
    Hansen J; Hald T
    Ugeskr Laeger; 1993 Dec; 155(50):4058-64. PubMed ID: 7505965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonsurgical treatment of prostatic hyperplasia.
    Geller J
    Cancer; 1992 Jul; 70(1 Suppl):339-45. PubMed ID: 1376202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pharmacotherapy in benign prostatic hyperplasia].
    Hauri D
    Ther Umsch; 1995 Jun; 52(6):378-82. PubMed ID: 7541566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Benign hypertrophy of the prostate: which treatment, for whom?].
    Schulman C
    Rev Med Brux; 1999 Sep; 20(4):A212-8. PubMed ID: 10523895
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Current drug therapy of benign prostatic hyperplasia].
    Schmidbauer CP; Madersbacher S
    Wien Med Wochenschr; 1996; 146(8):161-4. PubMed ID: 8767400
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
    Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
    Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical management of benign prostatic hyperplasia: a review.
    Magoha GA
    East Afr Med J; 1996 Jul; 73(7):453-6. PubMed ID: 8918007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Hormonal therapy of benign prostatic hyperplasia].
    Horninger W; Bartsch G
    Urologe A; 1995 Jan; 34(1):9-15. PubMed ID: 7533450
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Embryologic development of the prostate. Insights into the etiology and treatment of benign prostatic hyperplasia.
    Shapiro E
    Urol Clin North Am; 1990 Aug; 17(3):487-93. PubMed ID: 1695777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alpha adrenergic antagonists for the treatment of symptomatic BPH.
    Lepor H
    Int J Clin Pharmacol Ther Toxicol; 1989 Apr; 27(4):151-5. PubMed ID: 2469658
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Managing the progression of lower urinary tract symptoms/benign prostatic hyperplasia: therapeutic options for the man at risk.
    Emberton M; Zinner N; Michel MC; Gittelman M; Chung MK; Madersbacher S
    BJU Int; 2007 Aug; 100(2):249-53. PubMed ID: 17617135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apoptotic impact of alpha1-blockers on prostate cancer growth: a myth or an inviting reality?
    Tahmatzopoulos A; Kyprianou N
    Prostate; 2004 Apr; 59(1):91-100. PubMed ID: 14991869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Drug therapy of benign prostatic hyperplasia].
    Vahlensieck W; Fabricius PG; Hell U
    Fortschr Med; 1996 Nov; 114(31):407-11. PubMed ID: 9036092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of alpha blockers in the treatment of BPH: a critical review of clinical results.
    Von Heland M; Casale P
    Arch Esp Urol; 1994 Nov; 47(9):873-81; discussion 881-2. PubMed ID: 7530943
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical management of prostatic diseases.
    Schlegel PN
    Adv Intern Med; 1994; 39():569-601. PubMed ID: 7511322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Estrogen suppression as a pharmacotherapeutic strategy in the medical treatment of benign prostatic hyperplasia: evidence for its efficacy from studies with mepartricin.
    Boehm S; Nirnberger G; Ferrari P
    Wien Klin Wochenschr; 1998 Dec; 110(23):817-23. PubMed ID: 10025034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Androgens and estrogens: their interaction with stroma and epithelium of human benign prostatic hyperplasia and normal prostate.
    Krieg M; Bartsch W; Thomsen M; Voigt KD
    J Steroid Biochem; 1983 Jul; 19(1A):155-61. PubMed ID: 6193338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.